Podcasts about genetic sequencing

Frank Furnari, Ph.D., and Alexander Khalessi, M.D., M.B.A., discuss exciting advancements in brain cancer research, focusing on glioblastoma, an aggressive and challenging tumor. They highlight how specific genetic mutations drive tumor growth and how targeting these mutations could lead to new treatments. They also delve into cutting-edge therapies, including using light to activate drugs aimed at combating cancer. A central theme of the talk is the complexity and ever-changing nature of these tumors, which makes them difficult to treat. However, technological breakthroughs, like single-cell genetic sequencing and lab-grown tumor models, are providing scientists with valuable insights into tumor behavior, paving the way for more personalized and effective treatment options in the future. Series: "Stem Cell Channel" [Health and Medicine] [Show ID: 39871]

Frank Furnari, Ph.D., and Alexander Khalessi, M.D., M.B.A., discuss exciting advancements in brain cancer research, focusing on glioblastoma, an aggressive and challenging tumor. They highlight how specific genetic mutations drive tumor growth and how targeting these mutations could lead to new treatments. They also delve into cutting-edge therapies, including using light to activate drugs aimed at combating cancer. A central theme of the talk is the complexity and ever-changing nature of these tumors, which makes them difficult to treat. However, technological breakthroughs, like single-cell genetic sequencing and lab-grown tumor models, are providing scientists with valuable insights into tumor behavior, paving the way for more personalized and effective treatment options in the future. Series: "Stem Cell Channel" [Health and Medicine] [Show ID: 39871]

Frank Furnari, Ph.D., and Alexander Khalessi, M.D., M.B.A., discuss exciting advancements in brain cancer research, focusing on glioblastoma, an aggressive and challenging tumor. They highlight how specific genetic mutations drive tumor growth and how targeting these mutations could lead to new treatments. They also delve into cutting-edge therapies, including using light to activate drugs aimed at combating cancer. A central theme of the talk is the complexity and ever-changing nature of these tumors, which makes them difficult to treat. However, technological breakthroughs, like single-cell genetic sequencing and lab-grown tumor models, are providing scientists with valuable insights into tumor behavior, paving the way for more personalized and effective treatment options in the future. Series: "Stem Cell Channel" [Health and Medicine] [Show ID: 39871]

Frank Furnari, Ph.D., and Alexander Khalessi, M.D., M.B.A., discuss exciting advancements in brain cancer research, focusing on glioblastoma, an aggressive and challenging tumor. They highlight how specific genetic mutations drive tumor growth and how targeting these mutations could lead to new treatments. They also delve into cutting-edge therapies, including using light to activate drugs aimed at combating cancer. A central theme of the talk is the complexity and ever-changing nature of these tumors, which makes them difficult to treat. However, technological breakthroughs, like single-cell genetic sequencing and lab-grown tumor models, are providing scientists with valuable insights into tumor behavior, paving the way for more personalized and effective treatment options in the future. Series: "Stem Cell Channel" [Health and Medicine] [Show ID: 39871]

In this episode of Naked Genetics: A mammoth discovery in ancient DNA structure; on the subject of ancient DNA, what can we sequence for a centuries old body? And, in quirks of evolution, the animal that drinks its own offspring's blood... Like this podcast? Please help us by supporting the Naked Scientists

In this episode of ATP, Shambhavi Naik and Saurabh Todi discuss the recent completion of the 10,000 Genome Project and the importance of collecting such data for medical research. Do check out Takshashila's public policy courses: https://school.takshashila.org.in/courses We are @‌IVMPodcasts on Facebook, Twitter, & Instagram. https://twitter.com/IVMPodcasts https://www.instagram.com/ivmpodcasts/?hl=en https://www.facebook.com/ivmpodcasts/ You can check out our website at https://shows.ivmpodcasts.com/featured Follow the show across platforms: Spotify, Google Podcasts, Apple Podcasts, JioSaavn, Gaana, Amazon Music .Do share the word with your folks  See omnystudio.com/listener for privacy information.

Jack gets Verily co-founder Tom Stanis' take on the Alphabet unit's recent layoffs. Marc talks with Element Biosciences' CEO about price-slashing in the genetic-sequencing sector. And Lecia provides an update on how the government plans to end the public health emergency. In this week's social media minute, we weigh in on Damar Hamlin's tie-up with the AHA. Follow us on twitter: @MMMnews www.mmm-online.com

Navid Alipour is Co-founder and Managing Partner at Analytics Ventures, a Venture Formation Fund focused on starting new ventures with artificial intelligence and machine learning at their core. Prior to co-founding Analytics Ventures, he founded La Costa Investment Group, making investments in startups nationally. Through the founding of multiple Artificial Intelligence (AI) based companies like CureMetrix and CureMatch, Navid is a long-time entrepreneur in the AI space and looks to address the need between angel investors and big venture capital funds. He has a passion for finding scientists and academics who are domain experts in their respective fields and helping them turn their research into viable businesses, helping build companies from inception. Navid serves on the Board of Tech San Diego helping build the thriving eco-system in San Diego. He is also on the Board of CureMetrix, AV Lab, Kazuhm, Dynam.AI & AlphaTrAI. Navid is a sought-after panelist, judge, speaker, and moderator on the topics of venture capital and entrepreneurship at forums such as UCSD, USD, SDSU, CyberHive, HeraHub, MIT Forum, RSNA, U.S. News STEM Conference, and CONNECT. Navid holds a BA from UC San Diego, and a JD/MBA from the University of San Diego. https://www.curematch.com/about-us/

Navid Alipour is Co-founder and Managing Partner at Analytics Ventures, a Venture Formation Fund focused on starting new ventures with artificial intelligence and machine learning at their core. Prior to co-founding Analytics Ventures, he founded La Costa Investment Group, making investments in startups nationally. Through the founding of multiple Artificial Intelligence (AI) based companies like CureMetrix and CureMatch, Navid is a long-time entrepreneur in the AI space and looks to address the need between angel investors and big venture capital funds. He has a passion for finding scientists and academics who are domain experts in their respective fields and helping them turn their research into viable businesses, helping build companies from inception. Navid serves on the Board of Tech San Diego helping build the thriving eco-system in San Diego. He is also on the Board of CureMetrix, AV Lab, Kazuhm, Dynam.AI & AlphaTrAI. Navid is a sought-after panelist, judge, speaker, and moderator on the topics of venture capital and entrepreneurship at forums such as UCSD, USD, SDSU, CyberHive, HeraHub, MIT Forum, RSNA, U.S. News STEM Conference, and CONNECT. Navid holds a BA from UC San Diego, and a JD/MBA from the University of San Diego. https://www.curematch.com/about-us/

This week Patrick is joined by Baroness Nicola Blackwood, the first female MP for Oxford. She was elected by MPs of all parties to Chair the Commons Science and Technology Select Committee. Baroness Blackwood remains the youngest-ever select committee chair in British history and the only woman to have held that position. Nicola is chair of Genomics England and has been a champion for genomics and the life sciences in UK policy. This episode covers the past, present, and future of genomics in healthcare in the UK and some of the exciting initiatives on the horizon, including whole genome sequencing in newborn screening.

This week Patrick is joined by Baroness Nicola Blackwood, the first female MP for Oxford. She was elected by MPs of all parties to Chair the Commons Science and Technology Select Committee. Baroness Blackwood remains the youngest-ever select committee chair in British history and the only woman to have held that position. Nicola is chair of Genomics England and has been a champion for genomics and the life sciences in UK policy. This episode covers the past, present, and future of genomics in healthcare in the UK and some of the exciting initiatives on the horizon, including whole genome sequencing in newborn screening.

In this episode, guests Christine Ward, VP and Head of Oncology and Cell Therapy Precision & Translational Medicine at Takeda and Geoff Oxnard, Thoracic Oncologist and VP of Foundation Medicine talk to Patrick about Next Generation Sequencing (NGS) in precision oncology. Also covered are the impact of large-scale genetic datasets on patient diagnosis, data consortiums enabling pioneering discoveries, and the recent partnership between Takeda and Foundation Medicine.

In this episode, guests Christine Ward, VP and Head of Oncology and Cell Therapy Precision & Translational Medicine at Takeda and Geoff Oxnard, Thoracic Oncologist and VP of Foundation Medicine talk to Patrick about Next Generation Sequencing (NGS) in precision oncology. Also covered are the impact of large-scale genetic datasets on patient diagnosis, data consortiums enabling pioneering discoveries, and the recent partnership between Takeda and Foundation Medicine.

This week, Patrick speaks to Heidi Rehm who is at the top of the field of genome interpretation and medical genetics. She has been a pioneering figure in the curation and sharing of rare genomic datasets across a federated exchange known as The Genome Aggregation Database or gnomAD.

This week, Patrick speaks to Heidi Rehm, Chief Genomics Officer at Massachusetts General Hospital. Heidi is a leader in defining standards for the interpretation of sequence variants and is a principal investigator for Clinical Genome Resource, otherwise known as ClinGen. ClinGen provides free and publicly accessible resources to support gene and variant interpretation. Heidi also co-leads the Matchmaker Exchange, aiding gene discovery for rare diseases.

Dr Jessica Kissinger and her collaborators run some of the world's largest databases of multi-omic data from eukaryotic parasites. In this episode, we explore major findings in the field and Dr Kissinger's vision of large-scale interoperable datasets driving novel discoveries. Plus, Dr Kissinger shares her recent and personal experience of diagnosis with a rare disease, Ehlers-Danlos Syndrome, that puts everything into perspective.

Dr Jessica Kissinger and her collaborators run some of the world's largest databases of multi-omic data from eukaryotic parasites. In this episode, we explore major findings in the field and Dr Kissinger's vision of large-scale interoperable datasets driving novel discoveries. Plus, Dr Kissinger shares her recent and personal experience of diagnosis with a rare disease, Ehlers-Danlos Syndrome, that puts everything into perspective.

Doctors have been transplanting organs for decades, but can we transplant reprogrammed stem cells to rejuvenate the human body? This week Patrick discusses transcriptional reprogramming, and bit.bio's opti-ox technology that has the potential to create every cell type and help kickstart a cell therapy revolution. With Mark Kotter Ph.D., neurosurgeon, and CEO and Founder of bit.bio.

Doctors have been transplanting organs for decades, but can we transplant reprogrammed stem cells to rejuvenate the human body? This week Patrick discusses transcriptional reprogramming, and bit.bio's opti-ox technology that has the potential to create every cell type and help kickstart a cell therapy revolution. With Mark Kotter Ph.D., neurosurgeon, and CEO and Founder of bit.bio.

In the United States, cotton is a $7 billion annual crop grown in 17 states.  Cotton plants in the largest producing countries in the world – India, China, and the U.S. – are genetically very similar and, like other crops that lack diversity, can be at risk. Cultivated cotton around the world has been bred […]

About this Episode: This week's guest, Daphne Koller, is the Founder and CEO of Insitro - a company shifting the paradigm of new drug discovery using predictive models. Patrick and Daphne talk about why she founded Insitro, how to create unified datasets, and the importance of being realistic about drug discovery.

About this Episode: This week's guest, Daphne Koller, is the Founder and CEO of Insitro - a company shifting the paradigm of new drug discovery using predictive models. Patrick and Daphne talk about why she founded Insitro, how to create unified datasets, and the importance of being realistic about drug discovery.

This week's guest, Daniel MacArthur, is the Director of the Centre for Population Genomics at the Garvan Institute of Medical Research and Murdoch Children's Research Institute. Daniel and Patrick discuss the impact of large-scale genetic datasets on patient diagnosis and treating genetic subtypes of disease, the power of big data and consortiums to enable pioneering discoveries, and give advice for early career researchers thinking about the dichotomy between industry and academia.

This week's guest, Daniel MacArthur, is the Director of the Centre for Population Genomics at the Garvan Institute of Medical Research and Murdoch Children's Research Institute. Daniel and Patrick discuss the impact of large-scale genetic datasets on patient diagnosis and treating genetic subtypes of disease, the power of big data and consortiums to enable pioneering discoveries, and give advice for early career researchers thinking about the dichotomy between industry and academia.

This week Patrick is joined by Dietrich Stephan, Founder and CEO of NeuBase Therapeutics. They discuss how to overcome the challenges of 'un-druggable' diseases, how Neubase is cracking the druggable genome using its scalable technology, and how biotech companies are innovating to secure the investment needed to accelerate precision medicine during a challenging period for the industry.

This week Patrick is joined by Dietrich Stephan, Founder and CEO of NeuBase Therapeutics. They discuss how to overcome the challenges of 'un-druggable' diseases, how Neubase is cracking the druggable genome using its scalable technology, and how biotech companies are innovating to secure the investment needed to accelerate precision medicine during a challenging period for the industry.

From decoding the genetics of rare disease using computational methods, to understanding the non-coding and 'near-coding' genome, this week Patrick is joined by Nicky Whiffin, Group Leader at the Wellcome Centre for Human Genetics and Sir Henry Dale Fellow at the University of Oxford. They discuss what it's like to create a brand new research group and the potential impact of whole genome sequencing on diagnosis rates.

From decoding the genetics of rare disease using computational methods, to understanding the non-coding and 'near-coding' genome, this week Patrick is joined by Nicky Whiffin, Group Leader at the Wellcome Centre for Human Genetics and Sir Henry Dale Fellow at the University of Oxford. They discuss what it's like to create a brand new research group and the potential impact of whole genome sequencing on diagnosis rates.

This week Patrick is joined by Sir Peter Donnelly, CEO of Genomics PLC and Professor of Statistical Science at the University of Oxford. They discuss how to get from data to implementation in the clinic, the challenges of polygenic risk scores including prediction across different ethnic backgrounds, and the role of genomics in drug discovery.

This week Patrick is joined by Sir Peter Donnelly, CEO of Genomics PLC and Professor of Statistical Science at the University of Oxford. They discuss how to get from data to implementation in the clinic, the challenges of polygenic risk scores including prediction across different ethnic backgrounds, and the role of genomics in drug discovery.

This week Patrick is joined by three pioneering guests united by one ground-breaking project: the UK BioBank's Whole Genome Sequencing Project. Dr Mark Effingham, Deputy CEO of UK Biobank; Dr Kári Stefánsson, Founder and CEO of deCODE Genetics, and Professor Marylyn Ritchie, University of Pennsylvania, discuss the goals of the collaboration, it's challenges, and the potential it has to change the future of genomics research.

This week Patrick is joined by three pioneering guests united by one ground-breaking project: the UK BioBank's Whole Genome Sequencing Project. Dr Mark Effingham, Deputy CEO of UK Biobank; Dr Kári Stefánsson, Founder and CEO of deCODE Genetics, and Professor Marylyn Ritchie, University of Pennsylvania, discuss the goals of the collaboration, it's challenges, and the potential it has to change the future of genomics research.

In this week's episode of Clean Talk Podcast, Chad Neilsen (Director of Accreditation & Infection Prevention at UF Health Jacksonville and Public Health Officer for the Florida Air National Guard) will join to discuss his expertise on the infection prevention matter. Tune into to gain insight on topics including:• How infectious diseases in turtles led to Chad's trailblazing career in infection prevention.• Chad's current roles at UF Health Jacksonville and as a Public Health Officer for the Florida Air National Guard.• The opportunity to advise the governor's office and National Guard during the beginning of the COVID-19 pandemic.• What it was like working in the Active Reserve during the Ebola pandemic.• Preventing bio terrorism in major cities.• and more!Chad is the Director of Accreditation & Infection Prevention at UF Health Jacksonville, and a faculty member for the UF College of Medicine in Jacksonville. He is responsible for oversight of the facility's federal accreditation and UF Health Jacksonville's response to COVID-19. Chad also serves as a Public Health Officer for the Florida Air National Guard. His role in military epidemiology has included oversight of numerous outbreak and pandemic responses, including the Ebola Virus Disease outbreak of 2014, and more recently, in support of Florida's response to COVID-19. Don't miss out! Hear the discussion today!Chapters:0:00 Introduction0:51 Chad Neilsen's Professional Background1:48 Turtle Research Program2:55 Human VS. Turtle Epidemiology3:31 2014 Ebola Virus Pandemic5:30 Did the Ebola outbreak prepare you for COVID-19?6:35 What are some best practices for infection prevention?9:01 Has there been an increase in Hand Washing Hygiene?10:18 What is the Joint Commission and CMS?13:15 Is Bioterrorism a real threat?15:43 Experience consulting the State of Florida during COVID-19.16:58 Genetic Sequencing for pathogen traceability.18:27 How to prevent COVID-19.19:36 What else could be different in order to prevent infections?21:13 How has COVID-19 impacted higher education?23:50 Predictions for the future of Infection Prevention.26:44 Predictions for post-pandemic governmental roles.28:56 Words of advice for Infection Preventionists.30:03 OutroBe a Member of Our Community: https://cleantalk.onlineFind Out More Information: https://cleantalk.tvLinkedin: https://www.linkedin.com/company/sealshiledFacebook: https://www.facebook.com/SealShieldTwitter: https://twitter.com/SealShieldInstagram: https://www.instagram.com/sealshield/

This week's guest is Nathalie Kingston, Director of the NIHR BioResource. She talks to Patrick about how the scale of the BioResource has grown dramatically over the last nine years, her most exciting moments as Director to date, and how the BioResource is using Sano's technology to accelerate and support its research programmes.

This week's guest is Nathalie Kingston, Director of the NIHR BioResource. She talks to Patrick about how the scale of the BioResource has grown dramatically over the last nine years, her most exciting moments as Director to date, and how the BioResource is using Sano's technology to accelerate and support its research programmes.

National Institutes of Health (NIH) documents obtained by a nonprofit watchdog in a federal court suit reveal that the agency deleted CCP virus genetic sequencing information from the Wuhan Institute of Virology at the Chinese lab's request. https://ept.ms/3j3wngp

National Institutes of Health (NIH) documents obtained by a nonprofit watchdog in a federal court suit reveal that the agency deleted CCP virus genetic sequencing information from the Wuhan Institute of Virology at the Chinese lab’s request. The Arlington, Virginia-based Empower Oversight Whistleblowers and Researchers (EO) obtained, as a result of a Freedom of Information […]

Tatum Shank & Hollywood 4 Freedomhttps://www.hollywood4freedom.com/https://www.instagram.com/hollywood4freedom/ The Free America PodcastWebsite - https://www.freeamericapodcast.com/Bitchute - https://www.bitchute.com/channel/XUMguOqsBvbm/Rumble - https://rumble.com/user/FreeAmericaPodcastAlternate Social MediaGab - https://gab.com/FreeAmericaPodcastMewe - https://mewe.com/i/freeamerica2 Action ItemsHelp Pastor Artur - https://firebrandaction.com/artur-pawlowski-updatesContact Children's Hospital to Advocate for Teen Transplant - https://www.thegatewaypundit.com/2022/02/texas-childrens-hospital-reportedly-denies-teenagers-life-saving-kidney-transplant-unvaccinated/78 Ivermectin Studies - https://ivmmeta.com/New Bioweapon and the Cure - https://noqreport.com/2022/02/12/exclusive-dr-li-meng-yan-reveals-ccp-spreading-hemorrhagic-fever-bioweapon-via-olympics-and-she-shares-the-cure/ News Itemshttps://www.wnd.com/2022/02/graphic-trudeaus-forces-turn-violent-crush-elderly-woman-walker-appear-trample-crowd-beat-others/?utm_source=Email&utm_medium=wnd-breaking&utm_campaign=breaking&utm_content=breaking&ats_es=1c0954f1b62809b09a100d75c701d474https://www.rebelnews.com/leaked_rcmp_messages_time_for_the_protesters_to_hear_our_jackboots_on_the_groundhttps://www.thegatewaypundit.com/2022/02/trudeaus-deputy-chrystia-freeland-whose-grandfather-prominent-nazi-director-world-economic-forum-says-plans-make-emergency-powers-permanent/https://www.theepochtimes.com/biden-extends-us-national-emergency-over-covid-19_4290201.html?utm_source=News&utm_campaign=breaking-2022-02-20-3&utm_medium=email&est=QTVsHPdhxFkb806poNO%2BQ8TG49I3iYS5TYSpI5hJIUC7LRoPGgL53Zhz3us%3Dhttps://www.thegatewaypundit.com/2022/02/pandemic-wont-defined-end-newsom-unveils-californias-endemic-virus-policy-video/https://www.thegatewaypundit.com/2022/02/cdc-casually-admits-covid-nose-swabs-ended-lab-genomic-sequencing-analysis/https://www.theepochtimes.com/fda-executive-officer-says-us-government-plans-to-push-annual-covid-19-shots_4282659.html?utm_source=News&utm_campaign=breaking-2022-02-17-1&utm_medium=email&est=HvMsTJnESrCnGa9DZqE3JPHENfkYuD9f8MHitJOcN24HPx2RgtVhlu3%2BHz4%3Dhttps://www.thegatewaypundit.com/2022/02/project-veritas-fda-executive-officer-exposes-close-ties-agency-pharmaceutical-companies-video/https://www.lewrockwell.com/2022/02/no_author/triple-vaccinated-deaths-skyrocketed-495-in-january-80-of-all-new-covid-cases-are-fully-jabbed/https://www.thegatewaypundit.com/2022/02/anti-vaxx-concerns-prompt-scotlands-public-health-hide-data-covid-19-hospitalizations-deaths-vaccine-status/https://www.wnd.com/2022/02/4983444/?utm_source=Email&utm_medium=wnd-breaking&utm_campaign=breaking&utm_content=breaking&ats_es=1c0954f1b62809b09a100d75c701d474

Do you have questions about genetics that you always wanted to ask but never have? On this episode of Simply Walk The Talk, Josh delves deep into the world of genetic testing with Sloane Tilley of GeneSavvy - a start-up genetic testing company aiming to revolutionize the health and wellness industry by providing people with actionable insights into how to improve their wellbeing based on their unique genetic code. The two talk about the insights that can be gained from our genetics (including Sloane's own amazing personal experience!), the differences and interactions between genetics and epigenetics, the current gaps in commonly-used genetic tests, and much more! Enjoy the show

Today, in episode 437, our expert Infectious Disease and Community Medicine doctors discuss the latest on COVID-19. We talk about how nursing home booster vaccination rates have remained low, how obesity and other diet-related illness are affected by COVID-19, and how COVID genetic sequencing still lags. As always, join us for all the COVID-19 information you need, explained in clear terms by health experts. Website: NoiseFilter - Complex health topics explained simply (noisefiltershow.com) Animations: NoiseFilter - YouTube Instagram: NoiseFilter (@noisefiltershow) • Instagram photos and videos Facebook: NoiseFilter Show | Facebook TikTok: https://www.tiktok.com/@noisefiltershow --- Send in a voice message: https://anchor.fm/noisefilter/message

In the last episode of the year, Patrick joins forces with the host of the Personalized Medicine Podcast, Oleksandr Yagensky, to discuss six of the biggest and most exciting breakthroughs in genetics research in 2021. They talk about developments including cancer testing in healthy people, newborn genetic screening, AI and machine learning, stem cells, and more.

In the last episode of the year, Patrick joins forces with the host of the Personalized Medicine Podcast, Oleksandr Yagensky, to discuss six of the biggest and most exciting breakthroughs in genetics research in 2021. They talk about developments including cancer testing in healthy people, newborn genetic screening, AI and machine learning, stem cells, and more.

In this week's episode Patrick speaks to Quin Wills and Jack O' Meara, Co-Founders of Ochre Bio, about their founding story, why in-silico discoveries could be the road to faster and lower cost liver therapeutics, and the need for prioritising preventative measures against disease as the average human lifetime gets longer.

In this week's episode Patrick speaks to Quin Wills and Jack O' Meara, Co-Founders of Ochre Bio, about their founding story, why in-silico discoveries could be the road to faster and lower cost liver therapeutics, and the need for prioritising preventative measures against disease as the average human lifetime gets longer.

Can computer science help us live longer? It is a complex question that requires an understanding of our anticipated lifespan and how the health of our body at this moment compares to the average person our age, what some would call calculating our biological age. What computer science stands to help with is understanding how better to pinpoint that biological age and what factors may play into holding off the aging process. Guest Andy Lee, of NeuroInitiative and Vincere Biosciences, speaks with host Angelo Kastroulis about this hard problem of predicting our biological age and potentially reversing it.Angelo begins with a discussion on some of the classical age models that have previously looked at the question of determining one's biological age. He talks about classic papers by Horvath and Fahy that have changed the way scientists think about aging. He introduced the idea of epigenetics, or the study of the changes in living things that are caused by the medication of the way genes are expressed rather that the more classical mode of altering the genetic code itself. With his Guest Andy Lee, founding CTO of NeuroInitiative and COO of Vincere Biosciences, Angelo dives deeper into DNA methylation signatures and the patterns that we can look at to begin to determine someone's biological age. Andy describes how computer science and neural networks are modernizing these determinations and what that means for improving our longevity.The pair note the challenges posed by the sheer volume of genetic data and what advances in data science can make in our ability to push this area forward, including therapeutics for diseases such as Parkinson's. They talk about how computer science is allowing us to have transformative information brought to us so that then we can intervene and act on it.   About this Episode's GuestAndy Lee is Co-Founder, Director, and CTO of NeuroInitiative, where he is co-inventor on multiple granted and pending patents surrounding the SEED simulation platform, as well as COO at Vincere Biosciences, Inc., a Cambridge, MA, company developing disease-modifying therapies for Parkinson's disease. Previously, Andy was VP of Engineering at Black Knight through F500 acquisition, spin-out, and IPO. He has led teams of over 100 members and continues to actively code to create new data-driven solutions. You can find out more on Twitter (@Andy_D_Lee) and LinkedIn. CitationsFahy, GM, Brooke, RT, Watson, JP, et al. Reversal of epigenetic aging and immunosenescent trends in humans. Aging Cell. 2019; 18:e13028. https://doi.org/10.1111/acel.13028Horvath S. (2013). DNA methylation age of human tissues and cell types. Genome biology, 14(10), R115.https://doi.org/10.1186/gb-2013-14-10-r115Johnson, A.A., Shokhirev, M., and Shoshitaishvili, B. (August 2019). Revamping the Evolutionary Theories of Aging. Ageing Research Reviews. 55. Doi: 10.1016/j.arr.2019.100947.The Matt Walker Podcast. https://sleepdiplomat.com/podcast Further ReadingHandbook of Epigenetics, 2nd EditionNeuroInitiativeVincere BiosciencesAndy Lee on Twitter and LinkedIn About the HostAngelo Kastroulis is an award-winning technologist, inventor, entrepreneur, speaker, data scientist, and author best known for his high-performance computing and Health IT experience. He is the principal consultant, lead architect, and owner of Carrera Group, a consulting firm specializing in software modernization, event streaming (Kafka), big data, analytics (Spark, elastic Search, and Graph), and high-performance software development on many technical stacks (Java, .net, Scala, C++, and Rust). A Data Scientist at heart, trained at the Harvard Data Systems Lab, Angelo enjoys a research-driven approach to creating powerful, massively scalable applications and innovating new methods for superior performance. He loves to educate, discover, then see the knowledge through to practical implementation.Host:Angelo KastroulisExecutive Producer: Kerri Patterson; Producer: Leslie Jennings Rowley; Audio Engineer: Ryan Thompson; Communications Strategist: Albert PerrottaMusic: All Things Grow by Oliver Worth© 2021, Carrrera Group 

This week's guest, Paulo Fontes, is a Professor of Surgery and Chief Medical Officer at LyGenesis, an organ regeneration technology platform with a current focus on liver regeneration for patients with end stage liver disease. He talks to Patrick about how our lymph nodes can act as a 'bioreactor' to regrow functioning organs, how liver cells could be used in multiple transplants, and shares his thoughts on the future of organ transplants.

This week's guest, Paulo Fontes, is a Professor of Surgery and Chief Medical Officer at LyGenesis, an organ regeneration technology platform with a current focus on liver regeneration for patients with end stage liver disease. He talks to Patrick about how our lymph nodes can act as a 'bioreactor' to regrow functioning organs, how liver cells could be used in multiple transplants, and shares his thoughts on the future of organ transplants.

In this week's episode Patrick speaks to Director of the Big Data Institute at University of Oxford, Professor Cecilia Lindgren, about her biggest eureka moment, the power of collaboration and consortiums across academia and industry to grow genetic sample sizes and accelerate research, and the importance of best practice standards to enable genetic research to scale successfully.

In this week's episode Patrick speaks to Director of the Big Data Institute at University of Oxford, Professor Cecilia Lindgren, about her biggest eureka moment, the power of collaboration and consortiums across academia and industry to grow genetic sample sizes and accelerate research, and the importance of best practice standards to enable genetic research to scale successfully.

What is the role of genetics in Parkinson's disease? From the impact of variants in the LRRK2 gene, to the need to expand PD research in diverse populations to aid the development of new medicines, this week's guests, Dr Ignacio Mata and Dr James Beck, talk to Patrick about the history, and future, of precision medicine development in Parkinson's disease.

What is the role of genetics in Parkinson's disease? From the impact of variants in the LRRK2 gene, to the need to expand PD research in diverse populations to aid the development of new medicines, this week's guests, Dr Ignacio Mata and Dr James Beck, talk to Patrick about the history, and future, of precision medicine development in Parkinson's disease.

In this special episode we're sharing Patrick's guest appearance on GIANT's Healthy Innovators Podcast. He talks to the podcast's host, Barry Shrier, about the need to accelerate the development of new treatment options, how personalised medicine is changing the future of healthcare and what it takes to create a successful startup in the genomic medicine landscape.

In this special episode we're sharing Patrick's guest appearance on GIANT's Healthy Innovators Podcast. He talks to the podcast's host, Barry Shrier, about the need to accelerate the development of new treatment options, how personalised medicine is changing the future of healthcare and what it takes to create a successful startup in the genomic medicine landscape.

As more and more people get their DNA sequenced, through health care initiatives, biobanks and direct-to-consumer testing, an array of ethical questions arise. From how results are shared with research participants, to the ambiguities surrounding gene editing, Patrick and this week's guest, Dr Anna Lewis, Research Associate at the Edmond J. Safra Center for Ethics at Harvard, dive deep into the big questions surrounding genetics and medicine.

As more and more people get their DNA sequenced, through health care initiatives, biobanks and direct-to-consumer testing, an array of ethical questions arise. From how results are shared with research participants, to the ambiguities surrounding gene editing, Patrick and this week's guest, Dr Anna Lewis, Research Associate at the Edmond J. Safra Center for Ethics at Harvard, dive deep into the big questions surrounding genetics and medicine.

Representative Bennie Thompson leads the House committee to investigate the January 6th riot.Then, the Mississippi legislature prepares for redistricting.And, a look at COVID-19 genetic analysis. See acast.com/privacy for privacy and opt-out information.

Can the speed and success of COVID-19 trials teach us how to run other trials 5x faster going forward? Can polygenic risk scores be effectively integrated into healthcare systems? Why do 'unique datasets' hold the key to future drug discovery? And why is there a disparity between precision medicine development in cancer and all other disease areas? Dr Vineeta Agarwala, General Partner at the Andreessen Horowitz Bio Fund, answers all these questions and more as she discusses the future of biotech and genomic medicine with Patrick.

Can the speed and success of COVID-19 trials teach us how to run other trials 5x faster going forward? Can polygenic risk scores be effectively integrated into healthcare systems? Why do 'unique datasets' hold the key to future drug discovery? And why is there a disparity between precision medicine development in cancer and all other disease areas? Dr Vineeta Agarwala, General Partner at the Andreessen Horowitz Bio Fund, answers all these questions and more as she discusses the future of biotech and genomic medicine with Patrick.

On this episode of the podcast Patrick is joined by Robert Green, a geneticist, Professor of Medicine at Harvard, and Director of the Preventive Genomics Clinic at Brigham Health, whose work centers around accelerating evidence based implementation of genomic medicine. Through the Genomes2People research programme, Robert has led numerous randomised control trials of genetic sequencing in adults and newborns. Patrick and Robert discuss topics including testing for common complex disease risks in healthy adults, genetic testing for newborns, and what major barriers need to be overcome to realise the full potential of personalised medicine.

On this episode of the podcast Patrick is joined by Robert Green, a geneticist, Professor of Medicine at Harvard, and Director of the Preventive Genomics Clinic at Brigham Health, whose work centers around accelerating evidence based implementation of genomic medicine. Through the Genomes2People (https://www.genomes2people.org/) research programme, Robert has led numerous randomised control trials of genetic sequencing in adults and newborns. Patrick and Robert discuss topics including testing for common complex disease risks in healthy adults, genetic testing for newborns, and what major barriers need to be overcome to realise the full potential of personalised medicine.

Victoria's latest coronavirus cluster has continued to grow over huge areas of the state, but Health authorities say they are on top of the outbreak. COVID testing sites across the state are being so overrun, people are being turned away as authorities scramble to meet demand. Child's play based on butterflies and building blocks will be a key part of formal early learning under the first curriculum changes to daycare in a decade. And in sport, as David Warner fights to overcome a groin strain in time for the third Test against India on Thursday, fresh doubt has been cast over whether he'll be able to play out the series. For updates and breaking news throughout the day, take out a subscription atheraldsun.com.au See omnystudio.com/listener for privacy information.

We talk to a genetic testing company which may have cracked the code to digital privacy. Part 1: genes, eugenism, and the life-saving power of genomic sequencing. Part 2: genetic privacy, serial killers, and the holy grail of cryptography. FIND OUT MORE circagene.com Questions & comments? Email us at wcn@granttree.co.uk

Sergey Musienko is the founder and CEO of Atlas Biomed. They provide genetic sequencing and microbiome tests to monitor your health. Sergey is a graduate of the singularity university ran by Ray Kurzweil where he first started working on the idea for Atlas Biomed. They are now one of the leading sources of data and insights into health for the curious and health-conscious human. I have used their tests myself and can highly recommend the insights and the user interface of the website is simply fantastic. There is a tonne of complicated data that they boil down into a really accessible and interesting format. They provide all the key information for how to actively increase your health and life-span with cutting edge science. Insights The importance of genetics in getting to know an individual’s health. How efforts are being made to make medicine proactive rather than reactive. How genotyping can be used to find out the disease risks that individuals face due to genetic mutations? Multi-factorial traits and diseases – how genetic only partially affects them. Combining genetic information with personal data and health records to develop a holistic idea about one’s health. Gut bacteria – their importance, functions, effects, diversity, and even transplants. A diverse diet is essential to maintain one’s health for a long period of time. How Sergey’s company aims to push science Sergey and Atlas Biomed Connect on LinkedIn (https://www.linkedin.com/in/sergeymusienko/) Atlas Biomed (https://atlasbiomed.com/) ABOUT THE HOST My name is Sam Harris. I am a British entrepreneur, investor and explorer. From hitchhiking across Kazakstan to programming AI doctors I am always pushing myself in the spirit of curiosity and Growth. My background is in Biology and Psychology with a passion for improving the world and human behaviour. I have built and sold companies from an early age and love coming up with unique ways to make life more enjoyable and meaningful. Sam: Instagram (https://www.instagram.com/samjamsnaps/) Quora (https://www.quora.com/profile/Sam-Harris-58) Twitter (https://twitter.com/samharristweets) LinkedIn (https://www.linkedin.com/in/sharris48/) Sam's blog - SamWebsterHarris.com (https://samwebsterharris.com/) Support the Show - Patreon (https://www.patreon.com/growthmindset) Subscribe! If you enjoyed the podcast please subscribe and rate it. And of course, share with your friends! Special Guest: Sergey Musienko.

When he noticed that the technology to sequence genomes was severely under-untilized, Dennis Grishin and his Nebula cofounders sought out a way to bring this straight to consumers. Find out how they built their company to keep their users apprised of breaking scientific discoveries that may relate to their own genetics and overall health.

How do new technologies and techniques for altering DNA get used? And who gets to use them? In recent years, the development of inexpensive genetic sequencing and easy gene editing technologies has given rise to a community of non-academic, amateur researchers who like to refer to themselves, only half-jokingly, as “biohackers.” But, says Mildred Cho, a research professor who has published frequently about bioethics, such communities are not bound by traditional “first-do-no-harm” ethical norms that professional biologists and physicians adhere to. There is, for instance, a group of such do-it-yourself researchers pursuing a low-cost insulin substitute that is free of patent protection; they hope to bring that life-saving medicine to millions who cannot afford it. On the flip side, Cho says, there are also bio-hobbyists who like to do things “just for fun” that could present considerable danger to society. “Would you want your neighbor recreating polio in his garage?” she asks, rhetorically, adding that these deep and challenging concerns are better addressed sooner rather than later. Join bioethicists Mildred Cho and The Future of Everything host Russ Altman for a provocative discussion about the shifting landscape in the ethics of biological research. You can listen to The Future of Everything on Sirius XM Insight Channel 121, iTunes, Google Play, SoundCloud, Spotify, Stitcher or via Stanford Engineering Magazine.

Episode 019 The road to wholesale does not usually start with genetic sequencing, but Holly Kenny of Elsie Kaye Glassworks has made her own path with a torch in hand. Listen in as she shares how she continues to evolve her business to support both her creative expression and the market she serves. A little about Holly Holly Kenny has been creating unique artisan jewelry, giftware and kitchenware using a torch and glass rods since 2008.  She owns Elsie Kaye Glassworks, an artisan studio and gift shop that features the work of New England artisans. To learn more about Holly and Elsie Kaye Glassworks, you can visit https://elsiekaye.com/ (https://elsiekaye.com/) . Thoughts from Holly I’m most proud of developing an artist community here in my town, and my area because right around me there’s not whole lot of that… that’s been pretty amazing. Go after what you want. I was afraid it wouldn’t work, but just don’t be afraid to try it and see how it goes. Recommended Resources Lewis Howes School of Greatness (https://lewishowes.com/blog/) podcast Profiting by Design: A Jewelry Maker’s Guide to Business Success (https://www.amazon.com/Profiting-Design-Jewelry-Business-Success/dp/0971349592) by Marlene Richie Quotable “Don’t be afraid to ask for help and make sure that you surround yourself with really good people to help you do the things that you can’t do it.” “Focus on what you’re good at and not compromising the quality of the work that you do to grow bigger, but just focusing on what you do–do it well.”

Keith Baverstock is a physical chemist by training whose primary career interest lies in the effects of ionizing radiation on public health and genomic instability. He's carried out research with the World Health Organization and published several scientific articles, including Genes without Prominence: A Reappraisal of the Foundations of Biology. He joins the podcast today to discuss a variety of topics, including cellular and molecular genetics, the effects of ionizing radiation on cells, mutational damage to DNA, how phenotypic expression works and the influence of epigenetics on this process, what he believes to be the basis of cancer versus other types of diseases, and why a focus on environmental causes of disease is called for. Along the way, he shares information from past experiments that shed light on important inquiries in this field, and asks questions that encourage you to think deeply about these topics and how they influence our everyday lives. To learn more about Keith Baverstock's theories and work, visit his website at kbaverstock.org.

Most of the people who develop cancer are adults, although a significant number of children succumb too. The signs are though that childhood cancers could have a different origin than the adult disease, which might also mean they can be treated in a different way. Cambridge University's Sam Behjati suspects that tumours in children form from foetal tissue that has failed to mature properly. And by comparing the genetic instructions operating in normal and cancerous kidney cells from children and adults, he's tracked down evidence to support his theory and found a host of new avenues to explore... Like this podcast? Please help us by supporting the Naked Scientists

Most of the people who develop cancer are adults, although a significant number of children succumb too. The signs are though that childhood cancers could have a different origin than the adult disease, which might also mean they can be treated in a different way. Cambridge University's Sam Behjati suspects that tumours in children form from foetal tissue that has failed to mature properly. And by comparing the genetic instructions operating in normal and cancerous kidney cells from children and adults, he's tracked down evidence to support his theory and found a host of new avenues to explore... Like this podcast? Please help us by supporting the Naked Scientists

Genetic Sequencing of Tumors for Personalized Medicine with guest Dr. Janina Longtine January 7, 2018 Yale Cancer Center visit: http://www.yalecancercenter.org email: canceranswers@yale.edu call: 203-785-4095

Genetic Sequencing of Tumors for Personalized Medicine with guest Dr. Janina Longtine January 7, 2018 Yale Cancer Center visit: http://www.yalecancercenter.org email: canceranswers@yale.edu call: 203-785-4095

Genetic Sequencing of Tumors for Personalized Medicine with guest Dr. Janina Longtine January 7, 2018 Yale Cancer Center visit: http://www.yalecancercenter.org email: canceranswers@yale.edu call: 203-785-4095

JAMA Pediatrics Editors' Summary by Frederick Rivara, MD, MPH, Editor in Chief, and Dimitri Christakis, MD, MPH, Associate Editor, for the September 5, 2017 issue

Josephine Johnston is the director of research at the Hastings Center. Stephen Morrissey, the interviewer, is the Managing Editor of the Journal. J. Johnston, R.M. Farrell, and E. Parens. Supporting Women’s Autonomy in Prenatal Testing. N Engl J Med 2017;377:505-7.

Will genetic sequencing become standard procedure for diagnosing disease? by University of California

23andMe is one of the biggest providers of home genetic testing kits and if you live in the UK, it's the only one that also includes various genetic analyses relevant not just to ancestry, but also to health. After a previous ban, the Food and Drug Administration for the first time approved marketing of the 23andMe Genetic Health Risk tests for diseases in the US. Adam Rutherford talks to geneticist Professor Matthew Cobb of the University of Manchester and to medical ethicist Dr Sarah Chan of the University of Edinburgh about how useful this genetic information can be and about who owns the data. New research published this week has revealed something really quite bizarre about our own genomes: that we can survive normally with a considerable number of dysfunctional genes. We've got around 20,000 genes, and you might think that you need them all, as when they don't work, they could lead to a serious health condition. But from a study of more than 10,000 people from Pakistan more than 1300 mutations were found to have no effect on their health. Geneticist Robert Plenge explains the research. The Great Barrier Reef has taken another huge hit with a mass bleaching event occurring a second year in a row. Over two thirds of the reef is now seriously damaged. Professor Jorg Wiedenmann of the University of Southampton explains that if bleaching events continue to happen at this rate, the world's largest coral reef will never recover.

Today on the Farm Report, two chocolate experts call in to tell Erin all about what gives chocolate the "fine" label. Pam Williams and Dan Pearson founded Ecole Chocolat and Marañón Chocolate, respectively. Both of today's guests helped found the Fine Chocolate Industry Association and its recent initiative the Heirloom Cacao Preservation, which seeks to save pure cacao beans from extinction. Pearson discovered a source of 40% white cacao beans while working as a businessman (and sourcing bananas) in Peru. He learned of the bean's rarity after sending it to the USDA for genetic testing, and has since teamed up with Pam to raise awareness on the possibility of such fine beans' extinction.

Eric Law is the host for this edition which reports on the following news stories. Court of Appeal Publishes Case on WCAB Privilege. Court of Appeal Remands Case to Consider 22 Non MPN Reports. Task Force Issues 60 Citations to Illegally Uninsured Contractors. 15 Indicted In Alleged Compound Drug Fraud Scheme. Outpatient and ASC Fee Schedules Now Final. Health Insurers Balk at Genetic Sequencing. WCIRB Submits January 1, 2015 Regulatory and Pure Premium Rate Filing. Superior Court System Still Under Funded. WCIRB CEO Says Comp Vital Signs Are "Mixed". WCRI Study Identifies Predictors Of Injury Outcomes.

http://www.einstein.yu.edu - Harry Ostrer, M.D., discusses how genetic sequencing is changing the course of treatment for common diseases such as cancer, Alzheimer’s disease and heart disease by identifying individuals at higher risk. It can also play a role in personalizing treatment: sequencing the genome of a cancer, for example, can yield information that leads to personalized, targeted therapy. He addresses concerns that genetic information can affect employability or insurability and reviews existing safeguards. Dr. Ostrer is a professor of pathology and of genetics at Albert Einstein College of Medicine and director of genetic and genomic testing in clinical pathology at Montefiore Medical Center.